These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 17393558)

  • 1. Correlation between nasal bone length and nuchal translucency thickness.
    Maymon R; Levinsohn-Tavor O; Cuckle H; Tovbin Y; Dreazen E; Wiener Y; Herman A
    Prenat Diagn; 2007 Apr; 27(4):387. PubMed ID: 17393558
    [No Abstract]   [Full Text] [Related]  

  • 2. First-trimester ultrasonographic screening for trisomy 21 using fetal nuchal translucency and nasal bone.
    Sepulveda W; Wong AE; Dezerega V
    Obstet Gynecol; 2007 May; 109(5):1040-5. PubMed ID: 17470580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fetal nasal bone assessment in first trimester down syndrome screening.
    Has R; Kalelioglu I; Yuksel A; Ibrahimoglu L; Ermis H; Yildirim A
    Fetal Diagn Ther; 2008; 24(1):61-6. PubMed ID: 18504384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuchal translucency and nasal bone in first-trimester ultrasound screening for aneuploidy in multiple pregnancies.
    Sepulveda W; Wong AE; Casasbuenas A
    Ultrasound Obstet Gynecol; 2009 Feb; 33(2):152-6. PubMed ID: 18985621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of standardization in determining gestational age for prenatal screening.
    Koster MP; Van Leeuwen-Spruijt M; Wortelboer EJ; Stoutenbeek P; Elvers LH; Loeber JG; Visser GH; Schielen PC
    Ultrasound Obstet Gynecol; 2008 Oct; 32(5):607-11. PubMed ID: 18720453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Which contingent sequential screening protocol?
    Larsen SO; Christiansen M; Norgaard-Pedersen B
    Prenat Diagn; 2005 Dec; 25(12):1168-9; author reply 1169-70. PubMed ID: 16317663
    [No Abstract]   [Full Text] [Related]  

  • 7. [Trisomy 21, after a half century].
    Nau JY
    Rev Med Suisse; 2009 Feb; 5(190):380. PubMed ID: 19264068
    [No Abstract]   [Full Text] [Related]  

  • 8. On the current dilemma of Down syndrome screening.
    Rose NC
    Obstet Gynecol; 2006 Jan; 107(1):2-3. PubMed ID: 16394031
    [No Abstract]   [Full Text] [Related]  

  • 9. Screening and outcome of chromosomal abnormalities other than trisomy 21 in Northern Finland.
    Marttala J; Peuhkurinen S; Ranta JK; Laitinen P; Kokkonen HL; Honkasalo T; Ryynanen M
    Acta Obstet Gynecol Scand; 2011 Aug; 90(8):885-9. PubMed ID: 21539522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ethnic variation of fetal nasal bone length between 11-14 weeks' gestation.
    Collado F; Bombard A; Li V; Julliard K; Aptekar L; Weiner Z
    Prenat Diagn; 2005 Aug; 25(8):690-2. PubMed ID: 16050000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three stage contingent screening for Down syndrome.
    Huttly WJ; Morris JK; Bestwick JP; Wald NJ; Murphy K; Pandya PP
    Prenat Diagn; 2006 Dec; 26(12):1183; author reply 1184. PubMed ID: 17115454
    [No Abstract]   [Full Text] [Related]  

  • 12. First- and second-trimester screening: detection of aneuploidies other than Down syndrome.
    Breathnach FM; Malone FD; Lambert-Messerlian G; Cuckle HS; Porter TF; Nyberg DA; Comstock CH; Saade GR; Berkowitz RL; Klugman S; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Tripp T; Bianchi DW; D'Alton ME;
    Obstet Gynecol; 2007 Sep; 110(3):651-7. PubMed ID: 17766613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nasal bone measurement during the 1st trimester: is it useful?
    Kelekci S; Yazicioğlu HF; Oguz S; Inan I; Yilmaz B; Sönmez S
    Gynecol Obstet Invest; 2004; 58(2):91-5. PubMed ID: 15148450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prenatal screening for Down syndrome: from sequential to combined estimated risk].
    Jouannic JM; Benifla JL
    Gynecol Obstet Fertil; 2006 Jun; 34(6):467-9. PubMed ID: 16716636
    [No Abstract]   [Full Text] [Related]  

  • 15. Which contingent sequential screening protocol?
    Wright D; Bradbury I; Benn P; Cuckle H; Ritchie K
    Prenat Diagn; 2005 Jun; 25(6):520-1. PubMed ID: 15966050
    [No Abstract]   [Full Text] [Related]  

  • 16. What is the role of fetal nasal bone examination in the assessment of risk for trisomy 21 in clinical practice?
    Ville Y
    Am J Obstet Gynecol; 2006 Jul; 195(1):1-3. PubMed ID: 16813740
    [No Abstract]   [Full Text] [Related]  

  • 17. Nuchal translucency and first-trimester screening.
    Harry WG; Reed KL
    J Soc Gynecol Investig; 2006 Apr; 13(3):153-4. PubMed ID: 16638584
    [No Abstract]   [Full Text] [Related]  

  • 18. Hyperglycosylated-hCG (h-hCG) and Down syndrome screening in the first and second trimesters of pregnancy.
    Palomaki GE; Neveux LM; Haddow JE; Wyatt P
    Prenat Diagn; 2007 Sep; 27(9):808-13. PubMed ID: 17590886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality control at first trimester: is there something new?
    Salomon LJ; Bernard JP; Ville Y
    Am J Obstet Gynecol; 2008 Mar; 198(3):345-6; author reply 346. PubMed ID: 18313463
    [No Abstract]   [Full Text] [Related]  

  • 20. First-trimester screening for trisomy 21 using nuchal translucency and nasal bone evaluations in a selected and an unselected population.
    Sonek J; Cicero S; Nicolaides K
    Am J Obstet Gynecol; 2007 Jan; 196(1):e19. PubMed ID: 16996461
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.